$CBDW acquisition target Adnexus Biotechnologies Inc. is delighted to reveal the completion of a merger agreement to acquire Sanctum Therapeutics core technology assets for treating HIV and SARS-CoV-2. https://finance.yahoo.com/news/1606-corp-targ...00778.html